Mirmomen Shahram, Alavian Seyed-Moayed, Hajarizadeh Behzad, Kafaee Jafar, Yektaparast Babak, Zahedi Mohammad-Javad, Zand Vahid, Azami Ali-Akbar, Hosseini Mir Mohammad-Ali, Faridi Ali-Reza, Davari Kambiz, Hajibeigi Bashir
Gastrointestinal and Liver Research Center, Tehran University of Medical Sciences, Iran.
Arch Iran Med. 2006 Oct;9(4):319-23.
Though regular blood transfusion improves the overall survival of patients with beta-thalassemia, it carries a definite risk of infection with blood-borne viruses. We carried out this multicenter study to provide epidemiologic data on hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infection among Iranian beta-thalassemic patients. Moreover, HCV infection-associated risk factors were investigated in this population.
Seven hundred and thirty-two patients with beta-thalassemia major or beta-thalassemia intermedia, selected from five provinces of Iran including Tehran (n = 410), Kerman (n = 100), Qazvin (n = 95), Semnan (n = 81), and Zanjan (n = 46), were enrolled in this study. Using ELISA, their sera were tested for HBsAg, HBcAb, HBsAb, HCVAb, and HIVAb. The positive HCVAb results were confirmed by RIBA-2nd generation.
The study sample consisted of 413 males and 319 females, with a mean +/- SD age of 17.9 +/- 9.0 years. One hundred forty-one (19.3%) patients were HCVAb positive; 11 (1.5%) were HBsAg positive. No one was HIVAb positive. Univariate analysis showed that beta-thalassemia major (P = 0.01), older age (P = 0.001), longer transfusion duration (P = 0.000), HBsAg seropositivity (P = 0.03), and higher serum ferritin level (P = 0.002) were significantly associated with a higher prevalence of HCV. Furthermore, the prevalence of HCV infection dropped significantly after the implementation of blood donors screening (22.8% vs. 2.6%; P = 0.000). Using multivariate analysis, beta-thalassemia major (P = 0.002), age (P < 0.001), serum ferritin level (P < 0.001), as well as consumption of unscreened blood (P = 0.003), were independent factors associated with HCV infection.
The prevalence of HCV infection is much higher among Iranian beta-thalassemic patients as compared with HBV and HIV infections. Routine screening of donated blood for HCV is highly recommended.
尽管定期输血可提高β地中海贫血患者的总体生存率,但确实存在感染血源性病毒的风险。我们开展了这项多中心研究,以提供有关伊朗β地中海贫血患者中乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)和人类免疫缺陷病毒(HIV)感染的流行病学数据。此外,还对该人群中与HCV感染相关的危险因素进行了调查。
从伊朗五个省份(包括德黑兰(n = 410)、克尔曼(n = 100)、加兹温(n = 95)、塞姆南(n = 81)和赞詹(n = 46))选取了732例重型β地中海贫血或中间型β地中海贫血患者纳入本研究。采用酶联免疫吸附测定法(ELISA)检测他们血清中的乙肝表面抗原(HBsAg)、乙肝核心抗体(HBcAb)、乙肝表面抗体(HBsAb)、丙肝抗体(HCVAb)和艾滋病毒抗体(HIVAb)。HCVAb检测结果阳性者采用第二代重组免疫印迹法(RIBA-2)进行确认。
研究样本包括413例男性和319例女性,平均年龄±标准差为17.9±9.岁。141例(19.3%)患者HCVAb检测呈阳性;11例(1.5%)患者HBsAg检测呈阳性。无人HIVAb检测呈阳性。单因素分析显示,重型β地中海贫血(P = 0,01)、年龄较大(P = 0.001)、输血时间较长(P = 0.000)、HBsAg血清学阳性(P = 0.03)以及血清铁蛋白水平较高(P = 0.002)与HCV感染率较高显著相关。此外,实施献血者筛查后,HCV感染率显著下降(22.8%对2.6%;P = 0.000)。多因素分析显示,重型β地中海贫血(P = 0.002)、年龄(P < 0.001)、血清铁蛋白水平(P < 0.001)以及输注未筛查血液(P = 0.003)是与HCV感染相关的独立因素。
与HBV和HIV感染相比,伊朗β地中海贫血患者中HCV感染率要高得多。强烈建议对捐献血液进行HCV常规筛查。